A Phase 3 interventional study of eloralintide and tirzepatide and Eloralintide in Obesity, sponsored by Eli Lilly and Company. Not yet recruiting at 155 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.
6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's planned enrollment of 2,115 is above the median of 77 across 5,084 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,095 studies on the registry; 142 are open to participants now.
Of its 535 completed or terminated interventional studies of FDA-regulated products, 356 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have had within 90 days prior to screening:
Participants will receive EloraTZP subcutaneously (SC)
Drug: eloralintide and tirzepatide
Participants will receive EloraTZP SC
Drug: eloralintide and tirzepatide
Participants will receive EloraTZP SC
Drug: eloralintide and tirzepatide
Participants will receive EloraTZP SC
Drug: eloralintide and tirzepatide
Participants will receive EloraTZP SC
Drug: eloralintide and tirzepatide
Participants will receive tirzepatide SC
Drug: Tirzepatide
Participants will receive eloralintide SC
Drug: Eloralintide
Participants will receive placebo SC
Drug: Placebo
Drug pages: Eloralintide · Tirzepatide
Administered SC
Also known as: LY900043
Administered SC
Also known as: LY3841136
Administered SC
Also known as: LY3298176
Administered SC
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 100
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 100
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 100
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 100
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, Week 100
Percent Change from Baseline in Total Body Fat Mass
Time frame: Baseline, Week 100
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 100
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 100
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 100
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Week 100
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) Score
Time frame: Baseline, Week 100
Change from Baseline in EQ-5D-5L Score
Time frame: Baseline, Week 100
Change from Baseline in Eating Behaviors and Attitudes Questionnaire (EBAQ) Score
Time frame: Baseline, Week 100
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight
Time frame: Baseline, Week 100
Percentage of Participants with a Change in Medication Use
Time frame: Baseline through Week 100
Percentage of Participants who Develop Type 2 Diabetes
Time frame: Baseline through Week 100
Overall Functional Assessment of Chronic Illness Therapy, Item GP5 (FACT-GP5) Score
Time frame: Week 100
Pharmacokinetics (PK): Maximum Concentration of Eloralintide at Steady State (Cmax,ss)
Time frame: Baseline through Week 100
PK: Area Under the Concentration Versus Time Curve of Eloralintide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Time frame: Baseline through Week 100
PK: Maximum Concentration of Tirzepatide at Steady State (Cmax,ss)
Time frame: Baseline through Week 100
PK: Area Under the Concentration Versus Time Curve of Tirzepatide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Time frame: Baseline through Week 100
Showing the first 100 of 155 sites across 9 countries.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eloralintide · Tirzepatide